Risk of venous thromboembolism in users of hormone replacement therapy

Lancet

Volumn 348, Issue 9033, 1996, Pages 977-980

  Daly, Edel ^a   Vessey, Martin P ^a   Hawkins, Michael M ^b   Carson, Jeffrey L ^a   Gough, Parimala ^a   Marsh, Sally ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Childhood Cancer Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK; SOCIOECONOMICS; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0030581589     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07113-9     Document Type: Article

References (21)

1. 1 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 526.
2. 2 The Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-19.
3. 3 Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. JAMA 1979; 242: 1150-54.
4. 4 Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-79.
5. 5 Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.
6. 6 British National Formulary Number 28. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1995.
7. 7 Report of the RCOG Working Party on Prophylaxis against Thromboembolism in Gynaecology and Obstetrics. London: Chameleon Press, 1995.
8. 8 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
9. 9 OPCS. Standard occupational classification, volumes 1-3. London: HM Stationery Office, 1990.
10. 10 Breslow NE, Day NE. Statistical methods in cancer research I: analysis of case-control studies. Lyon: International Agency for Research on Cancer, 1980: 192-246.
11. 11 Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-36.
12. 12 Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-83.
13. 13 Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-87.
14. 14 Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiological studies. Am J Obstet Gynecol 1985; 152: 729-98.
15. 15 Banks E, Crossley B, English R, Richardson A. Women doctors' use of hormone replacement therapy: high prevalence of use is not confined to doctors. BMJ 1996; 312: 638.
16. 16 Compston JE. HRT and osteoporosis. Br Med Bull 1992; 48: 309-44.
17. 17 OPCS. 1993-based subpopulation projections. Series PP3, no 9, table 5. London: HM Stationery Office, 1995.
18. 18 Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199-210.
19. 19 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions Trial. JAMA 1995; 273: 199-208.
20. 20 Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
21. 21 Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247-59.